Zydus obtains USFDA nod for 0.75% Metronidazole Topical Cream

Zydus obtains USFDA nod for 0.75% Metronidazole Topical Cream

Zydus USFDA Nod For Metronidazole Topical Cream

Zydus Lifesciences Limited, along with its subsidiaries and affiliates, has recently received the green light from the United States Food and Drug Administration (USFDA) to produce and market Metronidazole Topical Cream, 0.75%, also known as MetroCream, 0.75%. The drug is an antibiotic used to treat rosacea, a common skin disorder that affects adults and causes redness, swelling, and pimples. Its active ingredients are expected to reduce the symptoms caused by rosacea by decreasing inflammation.

The drug will be manufactured in India at Zydus’ topical manufacturing facility located in Changodar, Ahmedabad. The US market for Metronidazole Topical Cream, 0.75% is estimated to be worth USD 25 million, based on annual sales data reported in February 2023 by IQVIA MAT.

This approval brings Zydus’ total number of approvals to 366, and the company has filed over 440 abbreviated new drug applications (ANDAs) since the start of the filing process in FY 2003-04. With this approval, Zydus aims to expand its reach and provide affordable and effective treatment options to patients in need.

About Zydus Lifesciences:

Zydus Lifesciences Ltd, previously known as Cadila Healthcare Limited, is a multinational pharmaceutical corporation based in Ahmedabad, India. Its primary focus is on the production of generic medicines. In 2020, the company achieved the 100th rank in the prestigious Fortune India 500 list, a testament to its success and status as a major player in the pharmaceutical industry.

For More Latest News Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *